Published in:
Open Access
06-09-2022 | Multiple Sclerosis | Commentary
Expert-Agreed Practical Recommendations on the Use of Cladribine
Authors:
Virginia Meca-Lallana, José M. García Domínguez, Rocío López Ruiz, Jesús Martín-Martínez, Adrián Arés Luque, Miguel A. Hernández Pérez, José M. Prieto González, Lamberto Landete Pascual, Jaume Sastre-Garriga
Published in:
Neurology and Therapy
|
Issue 4/2022
Login to get access
Abstract
Cladribine is a disease-modifying selective immune reconstitution oral therapy for adult patients with highly active relapsing multiple sclerosis (RMS). It was approved in the USA in 2019 and in Europe in 2017, thus there are still gaps in existing guidelines for using cladribine tablets in clinical practice. Nine experts with extensive experience in managing patients with multiple sclerosis in Spain identified some of the unanswered questions related to the real-life use of cladribine tablets. They reviewed the available clinical trial data and real-world evidence, including their own experiences of using cladribine, over the course of three virtual meetings held between November 2020 and January 2021. This article gathers their practical recommendations to aid treatment decision-making and optimise the use of cladribine tablets in patients with RMS. The consensus recommendations cover the following areas: candidate patient profiles, switching strategies (to and from cladribine), managing response to cladribine and safety considerations.